​

Faeth Therapeutics Stock (NASDAQ:FTH)

ForecastFinancialsChart
Faeth Therapeutics by TradingView

Previous Close

$39.00

52W Range

$7.45 - $41.16

50D Avg

$29.85

200D Avg

$21.70

Market Cap

$1.03B

Avg Vol (3M)

$245.29K

Beta

-0.28

Div Yield

-

FTH Company Profile

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Feb 04, 2021

Website

FTH Performance

FTH Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-22.29M$-31.66M$-37.06M
Net Income$-21.09M$-30.16M$-34.10M
EBITDA$-20.91M$-29.52M$-33.39M
Basic EPS$-16.72$-1.20$-1.22
Diluted EPS$-16.72$-1.20$-1.22

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
CLRBCellectar Biosciences, Inc.
IMNNImunon, Inc.
COCPCocrystal Pharma, Inc.
DWTXDogwood Therapeutics, Inc.
MRKRMarker Therapeutics, Inc.
CINGCingulate Inc.
TRAWTraws Pharma, Inc.
BOLTBolt Biotherapeutics, Inc.
EVGNEvogene Ltd.